Completed NA INTERVENTIONAL 1-arm NCT02763124

Pseudophakic Astigmatic Reduction With Verion-LenSx Arcuate Incisions

Sponsor: Alcon, a Novartis Company

Updated 10 times since 2017 Last updated: Oct 11, 2019 Started: May 31, 2016 Primary completion: Oct 31, 2016 Completion: Oct 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Astigmatism, this trial is completed. The trial is conducted by Alcon, a Novartis Company and has accumulated 10 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2023 — Jul 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA
Jan 2021 — Dec 2022 [monthly]

Completed NA

▶ Show 5 earlier versions

Dec 2019 — Jan 2021 [monthly]

Completed NA
Jun 2018 — Dec 2019 [monthly]

Completed NA
Sep 2017 — Jun 2018 [monthly]

Completed NA

Status: Recruiting → Completed · Phase: PHASE4 → NA
Feb 2017 — Sep 2017 [monthly]

Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE4

First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alcon, a Novartis Company
Gainesville Eye Associates

Data source: Gainesville Eye Associates

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gainesville, United States